Suzhou Yasheng Pharmaceutical Co., Ltd.
Suzhou Yasheng Pharmaceutical Co., Ltd.
Explore linked clinical trials.8 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Primitive, Peripheral, epithelial neoplasm, neoplasm, neuroblastoma, neuroepithelial neoplasm, primitive neuroectodermal tumor | Recruiting | Phase 1 / Phase 2 | 2026-08-21 | NCT05701306 | |
| APG-2449 in Patients With Advanced Solid Tumors | Adnexal Diseases, Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, adenoma, bronchial neoplasm, bronchogenic carcinoma, digestive system disorder, digestive system neoplasm, endocrine system disorder, epithelial neoplasm, esophageal cancer, esophageal disorder, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, lung disorder, lung neoplasm, malignant endocrine neoplasm, malignant mesothelioma, malignant pleural mesothelioma, mesothelial neoplasm, mesothelioma, neoplasm, non-small cell lung carcinoma, ovarian cancer, ovarian disorder, pleural neoplasm, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 1 | 2026-07-23 | NCT03917043 | |
| A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies | B-cell chronic lymphocytic leukemia, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, neoplasm, non-Hodgkin lymphoma | Active, not recruiting | Phase 1 | 2026-05-01 | NCT03913949 | |
| Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, myeloid neoplasm, neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-04-29 | NCT04501120 | |
| A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus. | systemic lupus erythematosus | Recruiting | Phase 1 / Phase 2 | 2025-12-16 | NCT06182969 | |
| A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients | EGFR Positive Non-small Cell Lung Cancer | Active, not recruiting | Phase 1 | 2025-10-01 | NCT04001777 | |
| APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors | Neoplasms by Histologic Type, Neoplasms, Adipose Tissue, Neoplasms, Connective and Soft Tissue, liposarcoma, neoplasm, sarcoma | Recruiting | Phase 1 / Phase 2 | 2025-02-26 | NCT04785196 | |
| A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS. | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, bone marrow disorder, hematologic disorder, leukemia, myelodysplastic syndrome, myeloid leukemia, neoplasm | Recruiting | Phase 1 | 2024-10-15 | NCT04275518 |